臨床整形外科59巻9号

2024年09月発行

特集 変形性関節症に対するBiologics

脂肪組織由来培養間葉系幹細胞(ASC)と間質血管細胞群(SVF)の臨床成績の比較

著者： 尾辻正樹¹ 中村憲正²

所属機関： ¹横浜ひざ関節症クリニック ²大阪保健医療大学付属彩都スポーツ医科学研究所

ページ範囲：P.1107 - P.1113

変形性関節症(OA)は進行性の疾患であり，薬物療法や理学療法などの保存療法にて効果が得られない場合，手術治療が選択されている．しかし，再生医療等安全性確保法の施行以来，細胞治療などのバイオセラピーが自由診療ベースで展開されている．幹細胞治療の選択肢として，非培養型の間質血管細胞群(SVF)と，採取組織から分離された幹細胞のみを培養し使用する培養幹細胞治療がある．両者の治療方法，および治療成績の比較を行った．

参考文献

1) Aronowitz JA, Lockhart RA, Hakakian CS. Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue. Springerplus 2015;4:713. doi:10.1186/s40064-015-1509-2.

2) Baer PC, Geiger H. Adipose-derived mesenchymal stromal/stem cells:tissue localization, characterization, and heterogeneity. Stem Cells Int 2012;2012:812693. doi:10.1155/2012/812693.

3) Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002;13(12):4279-95.

4) Aust L, Devlin B, Foster SJ, et al. Yield of human adipose-derived adult stem cells from liposuction aspirates. Cytotherapy 2004;6(1):7-14.

5) Zhu Y, Liu T, Song K, et al. Adipose-derived stem cell:a better stem cell than BMSC. Cell Biochem Funct 2008;26(6):664-75.

6) Melief SM, Zwaginga JJ, Fibbe WE, et al. Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med 2013;2(6):455-63.

7) Baglio SR, Pegtel DM, Baldini N. Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. Front Physiol 2012;3:359. doi:10.3389/fphys.2012.00359.

8) de Windt TS, Vonk LA, Slaper-Cortenbach ICM, et al. Allogeneic MSCs and recycled autologous chondrons mixed in a one-stage cartilage cell transplantion:a first-in-man trial in 35 patients. Stem Cells 2017;35(8):1984-93.

9) Zwolanek D, Satué M, Proell V, et al. Tracking mesenchymal stem cell contributions to regeneration in an immunocompetent cartilage regeneration model. JCI Insight 2017;2(20):e87322. doi:10.1172/jci.insight.87322.

10) Alicka M, Major P, Wysocki M, et al. Adipose-derived mesenchymal stem cells isolated from patients with type 2 diabetes show reduced “stemness” through an altered secretome profile, impaired anti-oxidative protection, and mitochondrial dynamics deterioration. J Clin Med 2019;8(6):765. doi:10.3390/jcm8060765.

11) Marędziak M, Marycz K, Tomaszewski KA, et al. The influence of aging on the regenerative potential of human adipose derived mesenchymal stem cells. Stem Cells Int 2016;2016:2152435. doi:10.1155/2016/2152435.

12) Sohni A, Verfaillie CM. Mesenchymal stem cells migration homing and tracking. Stem Cells Int 2013;2013:130763. doi:10.1155/2013/130763.

13) Holzbauer M, Priglinger E, Kølle ST, et al. Intra-articular application of autologous, fat-derived orthobiologics in the treatment of knee osteoarthritis:a systematic review. Cells 2024;13(9):750. doi:10.3390/cells13090750.

14) Fujita M, Matsumoto T, Sobajima S, et al. Clinical and radiological comparison of single and double intra-articular injection of adipose-derived stromal vascular fraction for knee osteoarthritis. Cell Transplant 2023;32:9636897231190175. doi:10.1177/09636897231190175.

15) Labarre KW, Zimmermann G. Infiltration of the Hoffa's fat pad with stromal vascular fraction in patients with osteoarthritis of the knee -results after one year of follow-up. Bone Rep 2022;16:101168. doi:10.1016/j.bonr.2022.101168.

16) Kim YS, Oh SM, Suh DS, et al. Cartilage lesion size and number of stromal vascular fraction (SVF) cells strongly influenced the SVF implantation outcomes in patients with knee osteoarthritis. J Exp Orthop 2023;10(1):28. doi:10.1186/s40634-023-00592-1.

17) Tsubosaka M, Matsumoto T, Sobajima S, et al. Comparison of clinical and imaging outcomes of different doses of adipose-derived stromal vascular fraction cell treatment for knee osteoarthritis. Cell Transplant 2021;30:9636897211067454. doi:10.1177/09636897211067454.

18) Jo CH, Lee YG, Shin WH, et al. Intra-articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee:a proof-of-concept clinical trial. Stem Cells 2014;32(5):1254-66.

19) Pers YM, Rackwitz L, Ferreira R, et al. Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee:a phase I dose-escalation trial. Stem Cells Transl Med 2016;5(7):847-56.

20) Orozco L, Munar A, Soler R, et al. Treatment of knee osteoarthritis with autologous mesenchymal stem cells:a pilot study. Transplantation 2013;95(12):1535-41.

21) Yokota N, Yamakawa M, Shirata T, et al. Clinical results following intra-articular injection of adipose-derived stromal vascular fraction cells in patients with osteoarthritis of the knee. Regen Ther 2017;6:108-12.

22) Yokota N, Hattori M, Ohtsuru T, et al. Comparative clinical outcomes after intra-articular injection with adipose-derived cultured stem cells or noncultured stromal vascular fraction for the treatment of knee osteoarthritis. Am J Sports Med 2019;47(11):2577-83.

23) Yokota N, Lyman S, Hanai H, et al. Clinical safety and effectiveness of adipose-derived stromal cell vs stromal vascular fraction injection for treatment of knee osteoarthritis:2-year results of parallel single-arm trials. Am J Sports Med 2022;50(10):2659-68.